Omalizumab in patients with severe asthma and persistent sputum eosinophilia

Omalizumab, a recombinant humanized monoclonal antibody targeting the IgE molecule, is the first biologic approved for moderate-to-severe allergic asthmatics, who remain uncontrolled despite high dose inhaled corticosteroid and bronchodilators. Steroid-sparing effect of omalizumab has not been demon...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Allergy Asthma Clin Immunol
Autores principales: Mukherjee, Manali, Kjarsgaard, Melanie, Radford, Katherine, Huang, Chynna, Leigh, Richard, Dorscheid, Delbert R., Lemiere, Catherine, Boulet, Louis-Philippe, Waserman, Susan, Martin, James, Nair, Parameswaran
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6448265/
https://ncbi.nlm.nih.gov/pubmed/30988677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13223-019-0337-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares